ocular

(Rac)-MGV354 (MGV354) 是 MGV354 的外消旋体，MGV354 是可溶性鸟苷酸环化酶活化剂，在 GTM-3E 和 CHO 细胞中 EC50分别为 5 nM 和小于 0.5 nM。

Bromfenac sodium hydrate (Bromfenac monosodium salt sesquihydrate) 是一种可口服的 COX 抑制剂，抑制 COX-1和COX-2的IC50值分别为 5.56 和 7.45 nM。它是一种溴化非甾体类抗炎药，有用于白内障的术后炎症和疼痛以及假晶状体囊状黄斑水肿的研究。

Bromfenac Sodium (AHR 10282R) 是可口服的COX 抑制剂，抑制COX-1和COX-2的IC50值分别为 5.56 和 7.45 nM。它是溴化非甾体类抗炎药，通常用于白内障的术后炎症和疼痛以及假晶状体囊状黄斑水肿的研究。

Ot-730（QLT 091568） 是一种新型选择性β阻滞剂前药，可用于研究眼部疾病。

Bunazosin Hydrochloride (E 1015) 是一种 α(1)-adrenoceptor 拮抗剂，用作全身性抗高血压药和降眼压药。

PG-11047 2HCl 是一种细胞凋亡刺激剂，可用于治疗泌尿生殖系统疾病、免疫系统疾病、遗传病与畸形、眼部疾病和血液及淋巴系统疾病，研究淋巴瘤和前列腺癌。

ot-730 HCl 是一种新型选择性β阻滞剂前药，可用于研究眼部疾病。

Omidenepag isopropyl (DE-117) 是一种选择性前列腺素 EP2 受体激动剂，是一种新型局部眼部降低血压的化合物。Omidenepag isopropyl 对 EP1，EP2 和 FP 受体有弱亲和力。Omidenepag isopropyl 可用于研究青光眼和高眼压症。

Difluprednate (Myser) 是一种可用于术后眼睛疼痛和炎症的皮质类固醇。

Tropicamide (Ro 1-7683) 是一种选择性的 M4毒蕈碱乙酰胆碱受体拮抗剂，作为滴眼剂使用时，会产生短效瞳孔扩张和睫状肌麻痹。

Diquafosol tetrasodium (INS365) 是一种 P2Y2 受体激动剂，可刺激眼组织粘蛋白的分泌。它可改善泪膜稳定性和视觉功能，作为干眼症的局部治疗。

Emedastine (LY188695) 是一种可口服的，选择性和高亲和力的组胺 H1受体拮抗剂，Ki 值为 1.3 nM。它是苯并咪唑衍生物，可用于过敏性鼻炎、过敏性皮肤疾病和过敏性结膜炎的研究。

Latanoprost (Xalatan) 是前列腺素 F2α 类似物，是一种前列腺素受体激动剂，能够降低眼内压。

Gentamicin (Centicin) 是一种广谱的氨基糖苷类抗生素，具有抗菌活性，抑制革兰氏阳性菌和革兰氏阴性细菌的生长，可用于研究眼部感染。

Brimonidine Tartrate (AGN190342 tartrate) 是一种 alpha2 Adrenergic Receptor (alpha2-AR) 受体激动剂。

Methyl-4-oxoretinoate 是一种合成的类视黄醇化合物，具有抗癌化合物，可可以诱导癌细胞分化和凋亡。Methyl-4-oxoretinoate 可用于治疗痤疮、牛皮癣和其他皮肤病。Methyl-4-oxoretinoate 具有治疗各种眼部疾病（如年龄相关性黄斑变性）的潜力。

Tetrahydrozoline (Tetryzoline) 是一种咪唑啉的衍生物，是一种 α-肾上腺素能 (α-adrenergic) 激动剂，能引起血管收缩，广泛用于研究鼻充血、结膜充血。

AL 8810 is an 11β-fluoro analog of prostaglandin F2α (PGF2α) which acts as a potent and selective antagonist at the FP receptor. AL 8810 ethyl amide is an analog of AL 8810 in which the C-1 carboxyl group has been modified to an N-ethyl amide. This modification is analogous to the PG N-ethyl amides, as typified by Bimatoprost, that have been introduced as alternative PG ocular hypotensive prodrugs. In contrast to AL 8810 which contracted the cat iris, AL 8810 ethyl amide showed no contraction activity at concentrations up to 10-4 M and did not antagonize the activity of PGF2α-ethanolamide in this system.

IRBP651-670（Interphotoreceptor retinoid-binding protein (651-670)）是IRBP（亦称为retinoid-binding protein 3）的肽段，参与色素再生，通过将视黄醇和视黄醛从光感受细胞传输到视网膜色素上皮。在C57BL 6小鼠中，利用IRBP651-670诱导自身免疫性葡萄膜炎，这些小鼠携带H-2b单体型。用IRBP651-670（300 µg 动物）免疫增加了小鼠眼部IL-1β、IL-6、IL-17、TNF-α和IFN-γ水平，免疫细胞浸润及光感受器损伤。

Thromboxane B3 (TXB3), the stable hydrolysis product of TXA3, is synthesized from eicosapentaenoic acid (EPA) through the action of COX and thromboxane synthase enzymes. This compound is biosynthesized in several tissues, including seminal vesicles, lungs, polymorphonuclear leukocytes (PMNL), and ocular tissues.

Naphazoline nitrate is an α1-Adrenergic receptor agonist. It also induces autophagy and necrotic cell death in erythroleukemia cells and inhibits erythroid differentiation. It used to treat congestion and ocular pathologies.

GAT229 is a positive allosteric modulator of cannabinoid receptor 1 (CB1) and the S-(-) enantiomer of the CB1 modulator GAT211. It does not activate the receptor on its own but enhances the binding and activity of CB agonists. GAT229 (1 μM) enhances the binding of the CB1 full agonist CP 55,940 to CHO cells expressing human recombinant CB1 (hCB1), as well as the activity of 2-arachidonoyl glycerol , arachidonoyl ethanolamide , and CP 55,940 in arrestin2 recruitment assays and increases ERK1 2 and PLCβ3 phosphorylation in HEK293 cells expressing hCB1. GAT229 (1 μM) enhances depolarization-induced suppression of excitation but does not inhibit excitatory postsynaptic currents (EPSCs) in murine autaptic hippocampal neurons. GAT229 (0.2%, topical) reduces intraocular pressure by 5.8 and 7.7 mm Hg after 6 and 12 hours, respectively, in a transgenic mouse model of ocular hypertension using nose, ear, eye mutation (nee) mice.

Bimatoprost is the Allergan trade name for 17-phenyl trinor prostaglandin F2α ethyl amide (17-phenyl trinor PGF2α ethyl amide), an F-series PG analog which has been approved for use as an ocular hypotensive drug. Oxidation of the C-15 hydroxyl group produces 15-keto-17-phenyl trinor PGF2α ethyl amide. 15-keto-17-phenyl trinor PGF2α ethyl amide is a potential metabolite of 17-phenyl trinor PGF2α ethyl amide when 17-phenyl trinor PGF2α ethyl amide is administered to intact animals. No pharmacological studies on 15-keto-17-phenyl trinor PGF2α ethyl amide have been reported.

A number of 17-phenyl trinor prostaglandin F2α (17-phenyl trinor PGF2α) derivatives have been approved for the treatment of glaucoma. Of these, the unsubstituted or meta-substituted aromatic derivatives are the most potent FP receptor agonists. 17-trifluoromethylphenyl trinor PGF2α bears an aromatic ring which is reminiscent of the trifluoromethyl-phenoxy ring of travoprost ((+)-fluprostenol isopropyl ester). As an ocular hypotensive agent, it would be expected that 17-trifluoromethylphenyl trinor PGF2α would act very much like the free acid of travoprost. 17-phenyl trinor PGF2α is a potent luteolytic and abortifacient, with a potency equal to or greater than fluprostenol and cloprostenol.